surpass trial tirzepatide Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the Clinical Program | Cardiovascular Diabetology Cardiovascular outcomes of semaglutide and

Bottom Line: Patients need to be cautious and understand microdosing is not evidence-based it has not been studied in clinical trials, McGowan says

in vivo, hypercoagulation decreased upon LC treatment (ElGendy 2014): hypothesized

Sever et al., 2019) and blood supply

( Conclusion In conclusion, the emerging observation that some complications of diabetes are associated with an hyperactivation of RAAS has provided the pathophysiological basis to study the effects of GLP1-RA and SGLT2-i on RAAS to better explain the cardio-reno-protective effect demonstrated by the clinical trials, beyond their role on glucose control

Future trials could help elucidate other potential benefits of GLP-1 drugs beyond sugar control

Survodutide is a dual glucagon and GLP-1 receptor agonist in development that targets a different receptor combination than tirzepatide